Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C1156
http://purl.obolibrary.org/obo/NCIT_C1156
|
|---|---|
| Preferred Name | Megestrol Acetate |
| Definitions |
The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells. |
|---|---|
| prefLabel | Megestrol Acetate
|
| label | Megestrol Acetate
|
| CHEBI_ID | CHEBI:6723
|
| PDQ_Closed_Trial_Search_ID | 43435
|
| code | C1156
|
| Has_Target | |
| prefixIRI | NCIT:C1156
|
| in_subset |
See more
See less
|
| Display_Name | Megestrol Acetate
|
| Preferred_Name | Megestrol Acetate
|
| FDA_UNII_Code | TJ2M0FR8ES
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C24H32O4
|
| Maps_To | Megestrol Acetate
|
| CAS_Registry | 595-33-5
|
| NSC Number | 71423
|
| NCI_Drug_Dictionary_ID | 43435
|
| Legacy Concept Name | Megestrol_Acetate
|
| type | |
| ALT_DEFINITION | A drug used to block estrogen and suppress the effects of estrogen and androgens. It is used to treat breast and endometrial cancer, and is being studied in the treatment of other types of cancer. It is also used to improve appetite in patients with cancer. Megace belongs to the group of hormones called progestins.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43435
|
| Accepted_Therapeutic_Use_For | Appetite enhancement, AIDS patients; Breast cancer, palliative treatment; Endometrial carcinoma, palliative treatment
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0065879
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |